Borgeson Blake sold $98K of RXRX
Borgeson Blake sold 30,000 shares of RECURSION PHARMACEUTICALS, INC. (RXRX) at $3.25 on 2026-08-04 under a Rule 10b5-1 trading plan.
How this was made
The 30-second read
Why it matters
The newest fact is the specific sale size (30,000 shares), price ($3.25), and that it was executed under a pre-arranged 10b5-1 plan.
Market read
Traders may note the insider sale for sentiment, but the 10b5-1 designation makes it less actionable as a fundamental catalyst.
What to watch
The filing does not indicate whether other insiders sold/bought around the same time, nor does it provide post-sale performance context; without that, signal quality is low.
Background
The article is a SEC Form 4 insider transaction disclosure for Recursion Pharmaceuticals, reported by a director.
Ticker impact
Recursion Pharmaceuticals director Borgeson Blake filed a Form 4 open-market sale of 30,000 shares at $3.25 on 2026-08-04.
Likely minimal near-term impact; any effect would be sentiment-driven rather than fundamental.
The filing is a routine Form 4 transaction, explicitly tied to a pre-arranged 10b5-1 plan, reducing interpretive weight.
Market effects
No clear sector read-through from a single 10b5-1 insider sale.
None indicated.
None indicated.
Counterpoint
Even with a 10b5-1 plan, repeated insider selling can still coincide with internal expectations of near-term liquidity needs or risk management.
Key entities
- issuerRecursion Pharmaceuticals, Inc.
Subject of the Form 4 insider transaction disclosure.
- insiderBorgeson Blake
Director who reported an open-market sale under a 10b5-1 plan.
